重症感染发热患儿宽松与限制性体温阈值:多中心随机临床预试验
该开放、平行组预试验在4个英国儿科重症监护病房(PICU)及转运服务中,纳入>28天至<16岁、接受呼吸支持和补氧的急诊PICU感染疑似患儿,随机分为宽松组(仅≥39.5°C时退热干预)与限制组(≥37.5°C时退热干预)。100例(72%)被随机,87%获继续参与同意。前48小时平均最高体温限制组38.4°C(95%CI 38.2-38.6)vs 宽松组38.8°C(95%CI 38.6-39.1),平均差0.5°C(0.2-0.8);方案偏离占6.8%(99/1438个6小时时段),多与恢复期患者舒适度相关;住院时间、器官支持时长和死亡率两组相似,无预设严重不良事件。员工和家长支持试验,包括免预先知情同意。
要点
- 前48小时平均最高体温:限制组38.4°C(95%CI 38.2-38.6)vs 宽松组38.8°C(95%CI 38.6-39.1),平均差0.5°C(0.2-0.8)。
- 方案偏离占6.8%(99/1438个6小时时段),主要与恢复期患者舒适度相关。
- 住院时间、器官支持时长和死亡率两组相似,无预设严重不良事件。
- 100例(72%)被随机,每月每中心11.1例,87例(87%)获继续参与同意。
- 员工(n=48)和家长(n=60)支持试验,包括免预先知情同意;建议仅纳入有创通气患儿至拔管期间。
适用人群与场景
- 急诊PICU入院、年龄>28天至<16岁、接受呼吸支持和补氧的疑似感染患儿;来自4个英国PICU及相关转运服务。
诊断标准与关键阈值
- 宽松组:仅在体温≥39.5°C时给予退热干预;限制组:体温≥37.5°C时给予退热干预;均在呼吸支持期间。
处置流程与药物剂量
- 退热干预阈值:宽松组≥39.5°C,限制组≥37.5°C;具体药物、剂量和给药途径原文未报告。
研究设计与关键结果
- 开放、平行组预试验,4个英国PICU及转运服务,纳入100例(72%)随机,每月每中心11.1例,87例(87%)获继续参与同意。
- 前48小时平均最高体温:限制组38.4°C(95%CI 38.2-38.6)vs 宽松组38.8°C(95%CI 38.6-39.1),平均差0.5°C(0.2-0.8)。
- 方案偏离占6.8%(99/1438个6小时时段),主要与恢复期患者舒适度相关。
- 住院时间、器官支持时长和死亡率两组相似;无预设严重不良事件。
- 员工(n=48)和家长(n=60)支持试验,包括免预先知情同意;建议仅纳入有创通气患儿至拔管期间。
证据类型、等级与局限
- 证据类型:多中心随机临床预试验(开放、平行组,嵌入混合方法研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,围绕退热干预最佳体温阈值的不确定性 relevant to many emergency PICU admissions;更宽松的策略与平均最高体温轻度升高相关。
- 作者认为,确定性试验应聚焦于最严重病例,这些病例中退热药很少仅用于镇痛作用。
- 员工建议仅纳入有创通气患儿至拔管期间。
指南或共识出处
- 试验注册号ISRCTN16022198,注册日期2017年8月14日。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Fever improves pathogen control at a significant metabolic cost. No randomized clinical trials (RCT) have compared fever treatment thresholds in critically ill children. We performed a pilot RCT to determine whether a definitive trial of a permissive approach to fever in comparison to current restrictive practice is feasible in critically ill children with suspected infection.
METHODS: An open, parallel-group pilot RCT with embedded mixed methods perspectives study in four UK paediatric intensive care units (PICUs) and associated retrieval services. Participants were emergency PICU admissions aged > 28 days to < 16 years receiving respiratory support and supplemental oxygen. Subjects were randomly assigned to permissive (antipyretic interventions only at ≥ 39.5 °C) or restrictive groups (antipyretic interventions at ≥ 37.5 °C) whilst on respiratory support. Parents were invited to complete a questionnaire or take part in an interview. Focus groups were conducted with staff at each unit. Outcomes were measures of feasibility: recruitment rate, protocol adherence and acceptability, between group separation of temperature and safety.
RESULTS: One hundred thirty-eight children met eligibility criteria of whom 100 (72%) were randomized (11.1 patients per month per site) without prior consent (RWPC). Consent to continue in the trial was obtained in 87 cases (87%). The mean maximum temperature (95% confidence interval) over the first 48 h was 38.4 °C (38.2-38.6) in the restrictive group and 38.8 °C (38.6-39.1) in the permissive group, a mean difference of 0.5 °C (0.2-0.8). Protocol deviations were observed in 6.8% (99/1438) of 6-h time periods and largely related to patient comfort in the recovery phase. Length of stay, duration of organ support and mortality were similar between groups. No pre-specified serious adverse events occurred. Staff (n = 48) and parents (n = 60) were supportive of the trial, including RWPC. Suggestions were made to only include invasively ventilated children for the duration of intubation.
CONCLUSION: Uncertainty around the optimal fever threshold for antipyretic intervention is relevant to many emergency PICU admissions. A more permissive approach was associated with a modest increase in mean maximum temperature. A definitive trial should focus on the most seriously ill cases in whom antipyretics are rarely used for their analgesic effects alone.
TRIAL REGISTRATION: ISRCTN16022198 . Registered on 14 August 2017.
参考来源
- Peters MJ, Woolfall K, Khan I, et al. Permissive versus restrictive temperature thresholds in critically ill children with fever and infection: a multicentre randomized clinical pilot trial. Crit Care. 2019. PMID: 30845977. doi:10.1186/s13054-019-2354-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。